Lupus

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, J Y-Y
Right arrow Articles by Deng, J-S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, J Y-Y
Right arrow Articles by Deng, J-S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Lupus, Vol. 11, No. 3, 168-174 (2002)
DOI: 10.1191/0961203302lu162oa

Anti-adenosine deaminase antibodies in lupus erythematosus

J Y-Y Lee

Department of Dermatology, National Cheng-Kung University, Taiwan, Republic of China

J Hempel

Department of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

J-S Deng

Department of Dermatology, University of Pittsburgh and VAMC, Department of Veterans Affairs Medical Center, University Drive C, Pittsburgh, PA 15240, USA. Jdeng{at}imap.pitt.edu

Adenosine deaminase (ADA) is an enzyme involved in purine metabolism and has a major role in the development and function of lymphoid cells. Congenital de" ciency of ADA results in severe immunode"ciency. Patients with congenital ADA de" ciency treated with polyethylene glycolconjugated bovine ADA develop antibodies to ADA. This leads us to investigate the role of antiADA antibodies in patients with systemic rheumatic diseases. Commercially available ADA was used in ELISA and immunoblots for detection of anti-ADA antibodies. Four out of 100 patients examined were positive for anti-ADA antibodies. Two of them had peripheral blood lymphopenia but the antibody levels did not appear to correlate with the lymphocyte counts. Immunoblotting revealed that the antibodies recognized a 40 kDa peptide of ADA, corresponding to ADA1, the major component of ADA. Af" nity-puri"ed antibodies were used to locate the distribution of ADA on Hep-2 cells and lymphocytes by indirect immuno‘ uorescence. Anti-ADA antibodies gave a distinct nuclear speckled pattern on acetone-"xed cells. With viable cell immuno‘ uorescence, antiADA antibodies also stained the cell surface of HEp-2 cells and lymphocytes, indicating surface expression of ADA. The anti-ADA antibodies failed to gain access into the cytoplasm or nuclei when added to the cultures of HEp-2 cells. In summary, this is the " rst report of detection of antiADA1 autoantibody which is a new type of ANA with discrete, speckled nuclear staining, but which may not be associated with lymphopenia.

Key Words: adenosine deaminase • lupus erythematosus


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 CVIHome page
O. Ozdemir, E. Lainka, T. Niehues, and M. Hershfield
Increasing importance of stem cell gene therapy in adenosine deaminase deficiency?
Clin. Vaccine Immunol., March 1, 2006; 13(3): 433 - 435.
[Full Text] [PDF]